Pyda M - Search Results

1

Characterization of Two Distinct Amorphous Forms of Valsartan by Solid-State NMR.

Skotnicki M, Apperley DC, Aguilar JA, Milanowski B, Pyda M, Hodgkinson P. Skotnicki M, et al. Among authors: pyda m. Mol Pharm. 2016 Jan 4;13(1):211-22. doi: 10.1021/acs.molpharmaceut.5b00646. Epub 2015 Dec 8. Mol Pharm. 2016. PMID: 26602457

2

Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry.

Skotnicki M, Gaweł A, Cebe P, Pyda M. Skotnicki M, et al. Among authors: pyda m. Drug Dev Ind Pharm. 2013 Oct;39(10):1508-14. doi: 10.3109/03639045.2012.704379. Epub 2012 Jul 18. Drug Dev Ind Pharm. 2013. PMID: 22803969

3

Bisoprolol and bisoprolol-valsartan compatibility studied by differential scanning calorimetry, nuclear magnetic resonance and X-ray powder diffractometry.

Skotnicki M, Aguilar JA, Pyda M, Hodgkinson P. Skotnicki M, et al. Among authors: pyda m. Pharm Res. 2015 Feb;32(2):414-29. doi: 10.1007/s11095-014-1471-7. Epub 2014 Aug 13. Pharm Res. 2015. PMID: 25115829 Free PMC article.

4

Physical Ageing of Amorphous Indapamide Characterised by Differential Scanning Calorimetry.

Drogoń A, Skotnicki M, Skotnicka A, Pyda M. Drogoń A, et al. Among authors: pyda m. Pharmaceutics. 2020 Aug 25;12(9):800. doi: 10.3390/pharmaceutics12090800. Pharmaceutics. 2020. PMID: 32854214 Free PMC article.

5

Physicochemical Characterization of a Co-Amorphous Atorvastatin-Irbesartan System with a Potential Application in Fixed-Dose Combination Therapy.

Skotnicki M, Jadach B, Skotnicka A, Milanowski B, Tajber L, Pyda M, Kujawski J. Skotnicki M, et al. Among authors: pyda m. Pharmaceutics. 2021 Jan 18;13(1):118. doi: 10.3390/pharmaceutics13010118. Pharmaceutics. 2021. PMID: 33477672 Free PMC article.

6

Application of advanced thermal analysis for characterization of crystalline and amorphous phases of carvedilol.

Skotnicki M, Czerniecka-Kubicka A, Neilsen G, Woodfield BF, Pyda M. Skotnicki M, et al. Among authors: pyda m. J Pharm Biomed Anal. 2022 Aug 5;217:114822. doi: 10.1016/j.jpba.2022.114822. Epub 2022 May 7. J Pharm Biomed Anal. 2022. PMID: 35550491 Free article.

7

Heat capacity of cytisine - the drug for smoking cessation.

Czerniecka-Kubicka A, Tutka P, Zarzyka I, Neilsen G, Woodfield BF, Skotnicki M, Pyda M. Czerniecka-Kubicka A, et al. Among authors: pyda m. Eur J Pharm Sci. 2023 Apr 1;183:106397. doi: 10.1016/j.ejps.2023.106397. Epub 2023 Feb 1. Eur J Pharm Sci. 2023. PMID: 36736465 Free article.

8

The cytisine-enriched poly(3-hydroxybutyrate) fibers for sustained-release dosage form.

Czerniecka-Kubicka A, Skotnicki M, Gonciarz W, Zarzyka I, Jadach B, Lovecká L, Maternia-Dudzik K, Kovářová M, Pyda M, Tutka P, Sedlařík V. Czerniecka-Kubicka A, et al. Among authors: pyda m. Int J Biol Macromol. 2023 Aug 1;245:125544. doi: 10.1016/j.ijbiomac.2023.125544. Epub 2023 Jun 24. Int J Biol Macromol. 2023. PMID: 37356682 Free article.

9

Physical Ageing of Amorphous Poly(lactic acid)-Indapamide System Studied by Differential Scanning Calorimetry.

Skotnicki M, Drogoń A, Lulek J, Pyda M. Skotnicki M, et al. Among authors: pyda m. Pharmaceutics. 2023 Sep 19;15(9):2341. doi: 10.3390/pharmaceutics15092341. Pharmaceutics. 2023. PMID: 37765312 Free PMC article.

10

PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest.

Borowska K, Laskowska B, Magoń A, Mysliwiec B, Pyda M, Wołowiec S. Borowska K, et al. Among authors: pyda m. Int J Pharm. 2010 Oct 15;398(1-2):185-9. doi: 10.1016/j.ijpharm.2010.07.019. Epub 2010 Jul 22. Int J Pharm. 2010. PMID: 20655371

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

111 results

Search Page